Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Chief Executive Officer | June 30, 2026 | July 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 30, 2026 · Filed July 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 461,425 |
Reported balance
After 2026-06-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 1,905 · Balance 461,425 F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2026 Filed Jul 1, 2026 20:30 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1,905 | $11.15 | $21,240.75 |
DisclosureSEC source: 0001822879-26-000006 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 461,425 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2026 through June 30, 2026. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 1, 2026. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:28 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 34,273 | $17.93 | $614,634.85 |
DisclosureSEC source: 0001822879-26-000004 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 459,520 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.665 USD to $18.37 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,607 | $13.31 | $74,603.38 |
DisclosureSEC source: 0001822879-26-000003 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,793 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.21 USD to $13.445 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Option (Right to Buy) · Derivative | 216,388 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001822879-26-000003 · primarydocument.xml · derivative · entry 3 Leonard Frank X · CIK 0001822879 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,388 Underlying: Ordinary Shares · 216,388 shares Expires 2036-03-03 F4 · derivative.exercise_date: Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:31 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001822879-26-000003 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 499,400 F1 · security: Represents restricted share units that are scheduled to vest in equal parts on the first, second and third anniversary of the grant date, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,232 | $13.49 | $97,581.38 |
DisclosureSEC source: 0001822879-26-000002 · primarydocument.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 349,400 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $13.3126 USD to $13.70 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 18,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001822879-26-000002 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,632 F3 · security: Represents vesting of performance-based restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 9,734 | $13.66 | $133,003.43 |
DisclosureSEC source: 0001822879-26-000002 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,011 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.45 USD to $13.97 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| November 01, 2025 Filed Nov 4, 2025 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 966 | $12.81 | $12,374.46 |
DisclosureSEC source: 0001822879-25-000006 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,745 F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 833 | $15.13 | $12,603.29 |
DisclosureSEC source: 0001562180-25-005188 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 348,711 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 20:10 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 179,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-004553 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 347,878 F1 · security: Represents restricted share units that are scheduled to vest in equal installments on June 4, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,879 | $19.01 | $35,721.86 |
DisclosureSEC source: 0001562180-25-004426 · primarydocument.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,452 F3 · price: On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 1,879 shares in multiple trades at prices ranging from $18.78 to $19.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,600 | $17.99 | $118,732.68 |
DisclosureSEC source: 0001562180-25-004426 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 170,331 F2 · price: On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 6,600 shares in multiple trades at prices ranging from $17.71 to $18.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:09 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 21,717 | $17.22 | $373,958.05 |
DisclosureSEC source: 0001562180-25-004426 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 176,931 F1 · price: On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 21,717 shares in multiple trades at prices ranging from $16.71 to $17.70. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:41 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 81,499 | $18.19 Strike: $18.19 | $1,482,466.81 |
DisclosureSEC source: 0001562180-25-002159 · primarydocument.xml · derivative · entry 2 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,499 Underlying: Ordinary Shares · 81,499 shares Expires 2035-03-03 F2 · shares: Options to buy 81,499 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:41 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 54,975 | $18.19 | $999,995.25 |
DisclosureSEC source: 0001562180-25-002159 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,648 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,527 | $18.54 | $46,841.23 |
DisclosureSEC source: 0001562180-25-001976 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,673 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: On the transaction date, the reporting person sold 2,527 shares in multiple trades at prices ranging from $18.02 to $18.9918. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 02:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,770 | $18.28 | $50,647.51 |
DisclosureSEC source: 0001562180-25-001915 · primarydocument.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,200 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: On February 28, 2025, the reporting person sold 2,770 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,770 | $18.28 | $50,647.51 |
DisclosureSEC source: 0001562180-25-001834 · primarydocument.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,200 F3 · price: On February 28, 2025, the reporting person sold 2,770 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,989 | $20.55 | $40,871.96 |
DisclosureSEC source: 0001562180-25-001915 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,970 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: On February 27, 2025, the reporting person sold 1,989 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,277 | $19.92 | $204,737.37 |
DisclosureSEC source: 0001562180-25-001915 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,959 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: On February 27, 2025, the reporting person sold 10,277 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,989 | $20.55 | $40,871.96 |
DisclosureSEC source: 0001562180-25-001834 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,970 F2 · price: On February 27, 2025, the reporting person sold 1,989 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,277 | $19.92 | $204,737.37 |
DisclosureSEC source: 0001562180-25-001834 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,959 F1 · price: On February 27, 2025, the reporting person sold 10,277 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 01, 2024 Filed Nov 4, 2024 21:34 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 598 | $15.94 | $9,530.74 |
DisclosureSEC source: 0001562180-24-007516 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,236 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.88 USD to $15.9603 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 28, 2024 Filed Aug 6, 2024 20:17 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1,736 | $12.24 | $21,248.64 |
DisclosureSEC source: 0001562180-24-006039 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,834 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:08 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 840 | $16.01 | $13,448.40 |
DisclosureSEC source: 0001562180-24-002247 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,098 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:08 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,679 | $16.03 | $26,909.17 |
DisclosureSEC source: 0001562180-24-002247 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,938 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:38 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,078 | $16.14 | $33,544.74 |
DisclosureSEC source: 0001562180-24-001988 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,617 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:38 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 156,348 | $16.30 Strike: $16.30 | $2,548,472.40 |
DisclosureSEC source: 0001562180-24-001988 · primarydocument.xml · derivative · entry 3 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,348 Underlying: Ordinary Shares · 156,348 shares Expires 2034-02-26 F3 · derivative.exercise_date: Options to buy 156,348 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:38 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 102,249 | $16.30 | $1,666,658.70 |
DisclosureSEC source: 0001562180-24-001988 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · EVP, Pres., Novocure Oncology 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,695 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 07, 2023 Filed Mar 7, 2023 21:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,315 | $75.59 | $174,999.42 |
DisclosureSEC source: 0001562180-23-002581 · primarydocument.xml · nonDerivative · entry 4 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,284 F3 · price: On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 2,315 shares in multiple trades at prices ranging from $75.33 to $75.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 07, 2023 Filed Mar 7, 2023 21:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 6,003 | $75.00 | $450,205.79 |
DisclosureSEC source: 0001562180-23-002581 · primarydocument.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,599 F2 · price: On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 6,003 shares in multiple trades at prices ranging from $74.33 to $75.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,059 | $77.64 | $159,858.91 |
DisclosureSEC source: 0001562180-23-002489 · primarydocument.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,893 F3 · security: Sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:37 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 11,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002489 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,952 F2 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 888 | $76.16 | $67,629.55 |
DisclosureSEC source: 0001562180-23-002581 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,602 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:52 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,403 | $76.16 | $335,329.84 |
DisclosureSEC source: 0001562180-23-002581 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,490 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 308 | $76.05 | $23,423.74 |
DisclosureSEC source: 0001562180-23-002359 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,988 F2 · price: On March 2, 2023 pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 308 shares in multiple trades at prices ranging from $75.95 to $76.14. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,799 | $75.32 | $286,153.98 |
DisclosureSEC source: 0001562180-23-002359 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,296 F1 · price: On March 2, 2023 pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 3,799 shares in multiple trades at prices ranging from $74.89 to $75.88. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:37 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 844 | $75.28 | $63,534.55 |
DisclosureSEC source: 0001562180-23-002489 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,144 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:01 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,684 | $76.36 | $128,594.28 |
DisclosureSEC source: 0001645113-23-000031 · wf-form4_167779444622406.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,095 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:01 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 30,971 | $76.97 Strike: $76.97 | $2,383,837.87 |
DisclosureSEC source: 0001645113-23-000031 · wf-form4_167779444622406.xml · derivative · entry 3 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,971 Underlying: Ordinary Shares · 30,971 shares Expires 2033-02-27 F3 · derivative.exercise_date: Options to buy 30,971 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:01 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 18,621 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000031 · wf-form4_167779444622406.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,779 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,183 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · derivative · entry 19 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,662 Underlying: Ordinary Shares · 7,183 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,183 | $0.00 Strike: $21.15 | $0.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · derivative · entry 18 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,479 Underlying: Ordinary Shares · 7,183 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,517 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · derivative · entry 17 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,517 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,500 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · derivative · entry 16 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,500 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,826 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · derivative · entry 15 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,826 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,183 | $120.00 | $861,960.00 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 14 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,158 F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,183 | $21.15 | $151,920.45 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 13 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 23:21 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,183 | $114.00 | $818,862.72 |
DisclosureSEC source: 0001645113-23-000009 · wf-form4_167330650457668.xml · nonDerivative · entry 12 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,158 F4 · price: On January 5, 2023, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 7,183 shares in multiple trades at prices ranging from $114.00 to $114.03. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.